


PHARMACEUTICAL 2020

Atreca Inc. Rank 118 of 362







PHARMACEUTICAL 2020

Atreca Inc. Rank 118 of 362



The relative strengths and weaknesses of Atreca Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Atreca Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 260% points. The greatest weakness of Atreca Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 91% points.

The company's Economic Capital Ratio, given in the ranking table, is -67%, being 236% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	176,119
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	7,947
Liabilities, Non-Current	0
Other Assets	13,825
Other Compr. Net Income	0
Other Expenses	130
Other Liabilities	816
Other Net Income	3,083
Property and Equipment	5,771
Research and Development	54,726
Revenues	2,134
Selling, General and Administrative Expense	17,845

Output Variable	Value in 1000 USD
Assets	195,715
Liabilities	8,763
Expenses	72,701
Stockholders Equity	186,952
Net Income	-67,484
Comprehensive Net Income	-67,484
Economic Capital Ratio	-67%